
WHAT IS CLAIMED IS:

1. A crystalline salt form of Compound (1)




~~2. The crystalline salt form according to claim 1, wherein the crystalline salt form is a hydrochloride, oxalate, maleate, sulfate, or mesylate salt.~~

~~3. The crystalline salt form according to claim 1,~~ wherein the crystalline salt form is a hydrochloride salt having an X-ray powder diffraction pattern comprising peaks at approximately 9.7, 10.1, 14.3, 15.0, 17.5, 18.9, 21.9, and 23.7 degrees 2θ.

~~4~~2. The crystalline salt ~~form~~ according to claim 1, wherein the crystalline salt form is a hydrochloride salt having a differential scanning calorimetry thermogram endotherm T_{onset} at approximately 252 °C and an X-ray powder diffraction pattern comprising peaks at approximately 9.7, 10.1, 14.3, 15.0, 17.5, 18.9, 21.9, and 23.7 degrees 2θ.

3. A crystalline salt form of Compound (1)



~~,5. The crystalline salt form according to claim 1, wherein the crystalline salt form is a oxalate salt having an X-ray powder diffraction pattern comprising peaks at approximately 11.7, 13.0, 15.4, 16.3, 19.6, 22.1, and 24.5 degrees 2θ.~~

~~6. The crystalline salt form according to claim 1, wherein the crystalline salt form is a oxalate salt having a differential scanning calorimetry thermogram endotherm T_{onset} at approximately 205 °C and an X-ray powder diffraction pattern comprising peaks at approximately 11.7, 13.0, 15.4, 16.3, 19.6, 22.1, and 24.5 degrees 2θ.~~

~~7. The crystalline salt form according to claim 1, wherein the crystalline salt form is a maleate salt having an X-ray powder diffraction pattern comprising peaks at approximately 8.0, 10.4, 12.4, 14.0, 15.3, 16.4, 19.3, 21.5, and 23.3 degrees 2θ.~~

~~8. The crystalline salt form according to claim 1, wherein the crystalline salt form is a maleate salt having a differential scanning calorimetry thermogram endotherm T_{onset} at approximately 193 °C and an X-ray powder diffraction pattern comprising peaks at approximately 8.0, 10.4, 12.4, 14.0, 15.3, 16.4, 19.3, 21.5, and 23.3 degrees 2θ.~~

~~9. The crystalline salt form according to claim 1,~~ wherein the crystalline salt form is a sulfate salt having an X-ray powder diffraction pattern comprising peaks at approximately 8.4, 12.6, 13.7, 16.7, 21.0, 21.8, 22.2, and 23.4 degrees 2θ.

~~10~~4. The crystalline salt form according to claim ~~1~~3, wherein the crystalline salt form is a sulfate salt having a differential scanning calorimetry thermogram endotherm T_{onset} at approximately 229 °C and an X-ray powder diffraction pattern comprising peaks at approximately 8.4, 12.6, 13.7, 16.7, 21.0, 21.8, 22.2, and 23.4 degrees 2θ.

~~11. The crystalline salt form according to claim 1, wherein the crystalline salt form is a mesylate salt having an X-ray powder diffraction pattern comprising peaks at approximately 7.9, 11.3, 12.6, 12.9, 14.7, 16.1, 20.0, and 20.7 degrees 2θ.~~

~~12. The crystalline salt form according to claim 1, wherein the crystalline salt form is a mesylate salt having a differential scanning calorimetry thermogram endotherm T_{onset} at approximately 238 °C and an X-ray powder diffraction pattern comprising peaks at approximately 7.9, 11.3, 12.6, 12.9, 14.7, 16.1, 20.0, and 20.7 degrees 2θ.~~

~~13~~5. A pharmaceutical composition comprising the crystalline salt form of any one of claims 1 to ~~12~~4, and a pharmaceutically acceptable carrier.

~~14~~6. The pharmaceutical composition of claim ~~13~~5, which is a single unit dosage form.

~~15~~7. The pharmaceutical composition according to claim ~~13~~5, wherein the crystalline salt form is in substantially pure form.

~~16~~8. Use of the pharmaceutical composition according to any one of claims 5 to 7 in the manufacture of a medicament for~~A method of~~ treating chronic pain, anxiety, insomnia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, and metabolic syndrome in a mammal~~ comprising administering to the mammal a therapeutically effective amount of the pharmaceutical composition according to claims 13 to 15~~.

~~17~~9. Use of a therapeutically-effective amount of the crystalline salt form according to any one of claims 1 to 4 in the manufacture of a medicament for~~A method of~~ treating chronic pain,

anxiety, insomnia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, and metabolic syndrome in a mammal comprising administering to the mammal ~~a pharmaceutical composition comprising a therapeutically effective amount of the crystalline salt form according to claims 1 to 12~~.

~~18~~10. The use ~~method~~ according to claim ~~17~~9, wherein the therapeutically-effective amount of the crystalline salt form is ~~about~~ 5 mg to ~~about~~ 500 mg.